
	Cancer Genetics, Inc., an early-stage diagnostics company, focuses on developing and commercializing proprietary genomic tests and services to improve and personalize the diagnosis, prognosis, and response to treatment of cancer. The company offers a range of services in various areas, including microarray based testing, a proprietary microarray tests for the detection of chromosomal abnormalities observed in chronic lymphocytic leukemia, small lymphocytic lymphoma diffuse large B-cell lymphoma, mantle cell lymphoma, and kidney cancer. It also provides molecular testing services, such as polymerase chain reaction, sequencing, and mutahine analysis to analyze DNA and RNA, as well as to follow progression of disease and response to therapy at the genetic level; and cytogenetics testing, a series of methods that analyze human chromosomes in order to identify malignancy. In addition, the company provides FISH testing, an analysis of abnormalities at the chromosomal and gene levels; and flow cytometry testing, an immuno phenotype analysis of specific markers inside cells. Further, it offers histology testing, a microscopic examination of stained tissue sections; cytology testing, a non-gynecological fluid preparation for microscopic evaluations; and IHC testing, an analysis of the distribution of tumor antigens in specific cell and tissue types. Additionally, the company provides various non-proprietary oncology-focused tests and laboratory services comprising molecular testing, sequencing mutational analysis, flow cytometry testing, histology testing, and cytology testing services to oncologists and pathologists in hospitals, cancer centers, and physician offices, as well as to biotech and pharmaceutical companies for their clinical trials. The company was founded in 1999 and is headquartered in Rutherford, New Jersey.
